NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
IPO Year: 2021
Exchange: NASDAQ
Website: neximmune.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/22/2022 | $21.00 → $13.00 | Outperform | Raymond James |
| 11/15/2021 | $30.00 → $21.00 | Outperform | Raymond James |
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also issued unregistered warra
GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq ru
A JDRF funded grant is being used to explore the combination of NexImmune's antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune's AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D). "We
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA , being held November 1-5, 2023. "We are pleased that abstracts highlighting recent advances in our AIM injectable program demonstrating the ability to generate broad polyclonal T cell responses from memory and naive populati
GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI) (the "Company") a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse stock split of the Company's common stock at a special meeting of the Company held on October 17, 2023. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market at 5:00 p.m. Eastern Time, on Wednesday, October 18, 2023. The Company'
Company retains core capabilities to continue to advance its nanoparticle injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseases GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that, in order to reduce its cash expenditures while continuing to pursue its existing strategic plan, its Board of Directors approved and its management is implementing an approximately 53% reduction in workforce, de
NEXI-001 data presented at ASCO 2023 demonstrates proof-of-concept in patients with relapsed AML after allogeneic hematopoietic cell transplantation (HCT) and refractory to additional chemotherapy or salvage treatments; one patient continues to show no evidence of disease at nine months Preclinical data demonstrates superior potency and durability when combining T cell engager (TCE) bispecific agents with AIM-expanded multi-tumor-antigen-specific T cell at low doses NIH collaboration demonstrates AIM antigen-target functional validation capability and the potential of CD8+ T cell therapies as future treatments for EBV-related non-malignant diseases, such as multiple sclerosis (MS) and system
- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 treatment related events as of May 2023 - Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 - Antigen-specific T cells persist in blood and bone marrow and maintain important phenotypes that are associated with anti-tumor effect and immunologic memory GAITHERSBURG, Md., June 05, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach
AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease Data suggests a potential therapeutic role for AIM multi-antigen-specific products in multiple sclerosis GAITHERSBURG, Md., May 22, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it will be presenting a poster at the Federation of Clinical Imm
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 Phase I data to be presented at ASCO 2023 in June GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today reported financial results for the first quarter 2023. "This is an exciting time for NexImmune, as we remain focused on progressing the development of novel approaches in the field of immunotherapy," said Kristi Jones, NexImmune's CEO.
4 - NexImmune, Inc. (0001538210) (Issuer)
Raymond James reiterated coverage of NexImmune with a rating of Outperform and set a new price target of $13.00 from $21.00 previously
Raymond James reiterated coverage of NexImmune with a rating of Outperform and set a new price target of $21.00 from $30.00 previously
Raymond James initiated coverage of NexImmune with a rating of Outperform and set a new price target of $30.00
Cantor Fitzgerald initiated coverage of NexImmune with a rating of Overweight and set a new price target of $35.00
25-NSE - NexImmune, Inc. (0001538210) (Subject)
EFFECT - NexImmune, Inc. (0001538210) (Filer)
S-8 POS - NexImmune, Inc. (0001538210) (Filer)
S-8 POS - NexImmune, Inc. (0001538210) (Filer)
S-8 POS - NexImmune, Inc. (0001538210) (Filer)
POS AM - NexImmune, Inc. (0001538210) (Filer)
8-K - NexImmune, Inc. (0001538210) (Filer)
8-K - NexImmune, Inc. (0001538210) (Filer)
10-Q - NexImmune, Inc. (0001538210) (Filer)
DEFA14A - NexImmune, Inc. (0001538210) (Filer)
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 completed enrollment in its final safety cohorts and all patients have been dosed; Company continues to follow patients and will announce data at or around an upcoming scientific conferenceCompany announces executive management changes as part of resource reallocation GAITHERSBURG, Md., March 28, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for t
Company announces a strategic shift to focus on advancing its AIM Direct Injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseasesInitiating a corporate resource reallocation to advance the AIM INJ platform, reduce operating expenses and extend cash runway through the third quarter of 2023 Pausing enrollment and initiation for the NEXI-001 and NEXI-003 trials, respectively, and pursuing external clinical development through potential academic and corporate partners GAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted
Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company's first solid tumor product candidate for the treatment of HPV-related cancersPlans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22Clinical updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 4Q22Company is prioritizing resources to support Company's lead product candidates, NEXI-001 and NEXI-003 GAITHERSBURG, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed t
Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated by year end 2021 and first half 2022Announced collaboration with Yale University Department of Immunobiology to explore use of AIM INJ in regard to regulation of Type 1 Diabetes GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for the third quarter of 2021. "We had another strong quarter as characterized by our c
GAITHERSBURG, Md., Nov. 08, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report third quarter financial results and provide a corporate update on Friday, November 12, 2021, via press release, prior to the market open. The press release will be accessible under the investor section of the NexImmune's website at www.neximmune.com. About NexImmune NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the
Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated in the second half of 2021 GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for the second quarter of 2021. "The first half of the year was a very productive period for
GAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report second quarter financial results and provide a corporate update on Monday, August 9, 2021, via press release, after market close. The press release will be accessible under the investor section of the NexImmune's website at www.neximmune.com. About NexImmune NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's
Clinical data updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 2H2022Investigational New Drug (IND) submission for NEXI-003, the Company's first product for solid tumors, planned for 1H2022Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H2022 GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported financial results for the first quarter of 2022. "This quarter, we hav
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director. "I am honored to join the board of NexImmune at this pivotal juncture in the Company's work," stated Dr. Gandhi. "I am excited to work with NexImmune's leadership on maximizing the potential of its novel technology in multip
GAITHERSBURG, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones has been appointed as the Company's Chief Executive Officer and a member of its Board of Directors. Her appointment follows the departure of Scott Carmer, who submitted his letter of resignation this week. "The Board is pleased to appoint Kristi Jones as our new Chief Executive Officer and member of the Board of Directors," said Sol J. Barer, Chairman of NexImmune's Board of Directors.
Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investo
SC 13D - NexImmune, Inc. (0001538210) (Subject)
SC 13G/A - NexImmune, Inc. (0001538210) (Subject)
SC 13G/A - NexImmune, Inc. (0001538210) (Subject)
SC 13G - NexImmune, Inc. (0001538210) (Subject)
SC 13G - NexImmune, Inc. (0001538210) (Subject)
SC 13G/A - NexImmune, Inc. (0001538210) (Subject)
SC 13G - NexImmune, Inc. (0001538210) (Subject)
SC 13G - NexImmune, Inc. (0001538210) (Subject)
SC 13G - NexImmune, Inc. (0001538210) (Subject)
SC 13G - NexImmune, Inc. (0001538210) (Subject)
4 - NexImmune, Inc. (0001538210) (Issuer)
3 - NexImmune, Inc. (0001538210) (Issuer)
4 - NexImmune, Inc. (0001538210) (Issuer)
3 - NexImmune, Inc. (0001538210) (Issuer)
4 - NexImmune, Inc. (0001538210) (Issuer)
4 - NexImmune, Inc. (0001538210) (Issuer)
4 - NexImmune, Inc. (0001538210) (Issuer)
4 - NexImmune, Inc. (0001538210) (Issuer)
4 - NexImmune, Inc. (0001538210) (Issuer)
4 - NexImmune, Inc. (0001538210) (Issuer)